Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Receivables (2016 - 2020)

Historic Change in Receivables for Viridian Therapeutics, Inc.\DE (VRDN) over the last 7 years, with Q4 2020 value amounting to -$48000.0.

  • Viridian Therapeutics, Inc.\DE's Change in Receivables rose 9448.91% to -$48000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was -$99000.0, marking a year-over-year decrease of 21785.71%. This contributed to the annual value of -$99000.0 for FY2020, which is 21785.71% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Change in Receivables of -$48000.0 as of Q4 2020, which was up 9448.91% from -$191000.0 recorded in Q3 2020.
  • Viridian Therapeutics, Inc.\DE's Change in Receivables' 5-year high stood at $3.4 million during Q1 2018, with a 5-year trough of -$3.6 million in Q2 2018.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's median Change in Receivables value was $53500.0 (recorded in 2016), while the average stood at $450.0.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Change in Receivables crashed by 204411.76% in 2016 and then surged by 736363.64% in 2017.
  • Viridian Therapeutics, Inc.\DE's Change in Receivables (Quarter) stood at $11000.0 in 2016, then skyrocketed by 7363.64% to $821000.0 in 2017, then plummeted by 265.41% to -$1.4 million in 2018, then soared by 35.86% to -$871000.0 in 2019, then soared by 94.49% to -$48000.0 in 2020.
  • Its Change in Receivables was -$48000.0 in Q4 2020, compared to -$191000.0 in Q3 2020 and $244000.0 in Q2 2020.